Posted: February 4, 2010

Manhattan Scientifics and Dr. Edward R. Flynn Featured in Article on Novel Early Cancer Detection and Treatment

(Nanowerk News) Manhattan Scientifics is pleased to post an article from the New Mexico Business Weekly describing the early cancer detection work of Dr. Edward R. Flynn.
The article describes how “Flynn is drawing on his experience as a nuclear physicist to develop new, ground-breaking technology that can detect breast, Prostate and ovarian cancers much earlier than current diagnostic techniques. Flynn’s technology is based on magnetic nano particles injected into the body. The particles carry antibodies that bind with cancer cells to pinpoint the exact location of diseases, both for diagnostics and for targeted therapies.”
Dr. Flynn’s research has been funded by Small Business Innovative Research Grants from the National Institutes of Health. Dr. Flynn stated, “I am confident that by partnering with Manhattan Scientifics now, our team will achieve the ultimate goals of the program.”
On October 20, 2009, Manhattan Scientifics and Dr. Flynn signed an initial Letter of Intent describing their intention to cooperate to commercializing products and technologies arising out of Dr. Flynn's work. The parties are finalizing a definitive agreement to move forward together.
About Manhattan Scientifics, Inc. located in New Mexico, New York and Montreal. The company is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The Company is presently developing commercial medical prosthetics applications for its ultra fine grain metals. Additionally, the Company intends to pursue and commercialize the cancer research work & nano medical applications developed by Edward R. Flynn.
Source: Manhattan Scientifics (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: